IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1543 
Small font sizeDefault font sizeIncrease font size
Navigate Here
    Next article
    Previous article
    Table of Contents

Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2067    
    Printed100    
    Emailed0    
    PDF Downloaded585    
    Comments [Add]    

Recommend this journal

 

 RESEARCH PAPER
Year : 1999  |  Volume : 31  |  Issue : 2  |  Page : 133-137

Antiasthmatic and antianaphylactic effect of E-721B, a herbal formulation



Correspondence Address:
S K Mitra


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objective: To evaluate the antiasthmatic and antianaphylactic activity of E-721B in various experimental models. Methods: The antiasthmatic and antianaphylactic activity of E-721B was studied on the active and passive anaphylaxis in rats, acetyl choline-induced bronchospasm in guinea pigs, anaphylactic shock-induced bronchospasm in guinea pigs and rats and on degranulation of mast cells by Compound 48/80. Results: Treatment with E-721B showed a dose dependent (at 50, 100, 250 and 500 mg/kg p.o.) beneficial effect on degranulation rate of actively and passively sensitized mesenteric mast cells of albino rats when challenged with antigen (horse serum). E-721B treatment for 7 days resulted in significant protection against acetylcholine aerosol-induced bronchospasm in guinea pigs. E-721B treatment for 10 and 14 days, in guinea pigs and rats respectively, offered marked protection against anaphylactic shock-induced bronchospasm. E 721B treatment also protected the mast cell disruption induced by Compound 48/80. Conclusion: Antiasthmatic and antianaphylactic activity of E-721B may be possibly due to the membrane stabilising potential, suppression of antibody production and inhibition of antigen induced histamine release.






[PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow